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In this study, we investigate the eﬀect of argan oil consumption on serum lipids, apolipoproteins (AI and B), CRP, and LDL
susceptibility to oxidation in type 2 diabetic patients which are known to have a high level of cardiovascular risk due to lipid
abnormalities and lipid peroxidation. For that, 86 type 2 diabetic patients with dyslipidemia were randomized to one group
consuming 25mL/day of argan oil during 3 weeks and control group consuming 20g/day of butter in breakfast. After argan oil
intervention, serum triglycerides decreased by 11.84%, (P = 0.001), total chol by 9.13%, (P = 0.01), and LDL-chol by 11.81%,
(P = 0.02). However, HDL-chol and Apo AI increased (10.51%, P = 0.01 and 9.40%, P = 0.045, resp.). Susceptibility of LDL
to lipid peroxidation was signiﬁcantly reduced by increasing of 20.95%, (P = 0.038) in lag phase after argan oil consumption. In
conclusion, we show for the ﬁrst time that consumption of argan oil may have an antiatherogenic eﬀect by improving lipids, and
the susceptibility of LDL to oxidation in type 2 diabetes patients with dyslipidemia, and can therefore be recommended in the
nutritional management of type 2 diabetes.
1.Introduction
Increased cardiovascular morbidity and mortality in patients
with type 2 diabetes is well established [1]. In Morocco, the
diabetes prevalence was 6.6% in 2000, while in 2003 it was
progressed to 10% [2].
Patients with type 2 diabetes have a high level of car-
diovascular risk due to lipid abnormalities and lipid perox-
idation which are responsible in the development of athero-
genesis. These lipid disorders include not only quantitative
but also qualitative abnormalities of lipoproteins. The main
quantitative abnormalities are increased triglyceride (TG)
levels and decreased HDL-cholesterol (HDL-chol) levels [3,
4]. The main qualitative abnormalities include large very
low density lipoprotein (VLDL) particles, relatively rich in
triglycerides, small dense low density lipoprotein (LDL)
particles, increased triglyceride content of LDL and high
density lipoprotein (HDL), glycation of apolipoproteins,
and increased susceptibility of LDL to oxidation [5]. The
American Diabetes Association (ADA) has set desirable
LDL cholesterol (LDL-chol), HDL-chol, and TG levels
as <100, >40 in men/>50 in women, and <150mg/dL,
respectively [6]. Apolipoprotein B (Apo B) reﬂects the
total mass of atherogenic particles (VLDL, Intermediate
density lipoprotein (IDL), and LDL) and is associated with
cardiovascular disease (CVD) independently of LDL-chol
levels [7, 8]. In type 2 diabetes patients without other major
CVD risk factors, Apo B should be <90mg/dL. In case of
diabetes associated with one or more other cardiovascular
risk factors, Apo B should not exceed 80mg/dL [9]. Some
authors have suggested that in type 2 diabetics compared
to healthy controls, LDL is more susceptible to oxidation,
and diabetic patients have higher levels of oxidation which
may contribute to the more aggressive atherosclerosis when2 International Journal of Endocrinology
compared to nondiabetics [10]. Apolipoprotein AI (Apo AI)
is the major component of HDL constituting 45% of its
molecular mass and is responsible for its antiatherogenic
property by acting as a cofactor for the enzyme lecithin
cholesterol acyltransferase (LCAT) and as a mediator in
transfer of cholesterol from cells to HDL particles, which are
key steps involved in reverse cholesterol transport [11]. It is
known that in diabetic patients, the plasma concentration of
Apo AI is lower compared with healthy subjects [12]. The
Apo B/Apo AI ratio may represent the balance between pro-
atherogenic and antiatherogenic lipoproteins [13]. The Apo
B/Apo AI ratio has been reported to predict cardiovascular
risk better than cholesterol value [14]. The pathophysiology
of lipid abnormalities in type 2 diabetes is not yet totally
explained. However, insulin resistance and the “relative”
insulin deﬁciency, observed in patients’ with type 2 diabetes,
arelikely playing a crucialrole since insulin has animportant
function in the regulation of lipid metabolism [5]. The C-
reactive protein (CRP), an inﬂammatory marker, is known
to play a role in the insulin resistance [15]. Indeed, several
studies showed that the association of CRP with insulin
resistance was independent of obesity [16].
The diet and lifestyle are an integral part of any diabetes
management plan [17]. In the traditional Moroccan diet,
argan oil (extracted from Argania spinosa, an endemic
tree of south-western Morocco) is usually consumed at
breakfast, especially in the south-western region of the
country. Generally, this oil is rich in unsaturated fatty acids
(UFA), principally oleic and linoleic acids (44.8 and 33.7%,
resp.) [18]. Interestingly, the unsaponiﬁable fraction (1% of
the oil constituents) of argan oil is mainly rich in antioxidant
compounds such as tocopherols, which are present in a
higher proportion compared to olive oil (637mg/kg versus
258mg/kg, resp.) and especially in its γ-isoform (75%) [18].
The quality of fatty acids present in argan oil and their
composition in antioxidants give it a special signiﬁcance in
the nutritional prevention of CVD and other diseases [19–
25]. Consumption of argan oil could contribute to reduce
the risk in patients at high cardiovascular risk. The recent
data, published by our team, have shown the beneﬁcial eﬀect
of argan oil on lipid proﬁle and LDL susceptibility to lipid
peroxidation in healthy subjects and dylipidemic patients.
That why we were interested to evaluate its eﬀects in type 2
diabetic patients with dyslipidemia.
2. Patientsand Methods
2.1. Patients. The study protocol was approved by the
regional Committee for Ethics. This study was conducted
on diabetic patients with dyslipidemia aged 40–80 years
consulting the endocrinology department (Ibn Sina univer-
sity hospital, Rabat, Morocco). Exclusion criteria include
presence of hepatic or renal disease, myocardial infarction,
cigarette smoking, use of dietary antioxidant supplements,
andtreatmentwithinsulin,lipidloweringdrugs,orhormone
therapy during the preceding 6 months. The protocol and
objectives of this study were explained to the participants
in detail. Among 127 patients, a total of 86 diabetic
patients without any diabetes cardiovascular complications
Table 1: Chemical composition of argan oil [22].
Fatty acids %
C 16:0 13.4
C1 8:0 5 . 1
C 18:1 44.8
C 18:2 35.7
C1 8:3 0 . 1
Sterols mg/100 g oil
Schottenol 142
Spinasterol 115
Stigmasta-8,22-dien-3β-ol 9
Other 29
Tocopherols mg/Kg oil
α 35
β 122
γ 480
Phenolics compound μg/Kg oil
Vanilic acid 67
Syringic acid 37
Ferulic acid 3147
Tyrosol 12
(retinopathy, nephropathy, and myocardial infarction) com-
pleted the study and 41 dropped out because of personal
reasons.Duringthisstudy,thedailyhabitsoftheparticipants
such as physical activities, number of sleeping hours, and
working time were not changed. All patients were informed
verbally and in writing, and all patients signed an informed
consent form before entering the study.
2.2. Design. Study design (Figure 1) was two diet periods.
In the ﬁrst diet period for 2 weeks (baseline diet), all the
patients consumed 20g/day of butter with toasted bread
for breakfast. In the second diet period for 3 weeks, the
patientswererandomizedtotwodietgroups:onegroupof43
patients consuming 25mL/day of argan oil (argan oil group)
at breakfast, and the second group of 43 patients consuming
25g/day of butter (control group).
2.3. Biological Materials. The argan oil supplied and dis-
tributed to the participants was purchased from the same
origin and was extracted by industrial process [26]. Its fatty
acid and minor components composition is presented in
Table 1 [22].
2.4. Blood Collection. At the end of each diet period, venous
blood was collected into draw tubes after 12h fast. Plasma
was obtained by centrifugation for 12min for 4000rpm.
Plasma samples were stored at −20◦C until analysis.
2.5. Food Questionnaire. All of patients have been investi-
gated in relation to their daily eating habits through a com-
prehensive food questionnaire covering all foods commonly
consumed in Morocco and covers all meals and snacks daily.International Journal of Endocrinology 3
189 type 2 diabetic patients identiﬁed by questionnaire and clinic sheet
127 type 2 diabetic patients enrolled in this study
86 type 2 diabetic patients completed this study
62 had the exclusionary criteria of this study
41 dropped out because of personal reasons
Stabilization period = 2weeks (20g/day of butter)
Test group (25mL/day of argan oil during 3weeks) (n = 43) Control group (20g/day of butter during 3weeks) (n = 43)
Figure 1: Design of study.
2.6. Measurements. Demographic and anthropometric pa-
rameters (age, sex, weight, body mass index (BMI), waist
circumference) were evaluated in the patients at baseline.
Serumtotal-chol(TC)andHDL-chollevelsweredetermined
b ye n z y m a t i cc o l o r i m e t r i cp r o c e d u r eo fR i c h m o n d[ 27]
(Randox cholesterol enzymatic kit for cholesterol, and
Randox HDL cholesterol precipitant for HDL-C; Crum-
lin Co., Antrim, UK) adapted for a spectrophotometer
(Helios). Serum triglycerides were quantiﬁed by an enzy-
matic colorimetric procedure of Trinder [28]. (Randox,
triglycerides enzymatic kit, Crumlin Co, Antrim United
Kingdom). In contrast, LDL-chol was obtained by the
Friedewald formula [29], that is, LDL-chol=total choles-
terol−(triglycerides/5)−HDL-chol. Plasma Apo A1 and
Apo B were measured by immunoturbidimetry [30–33]
(Cobas Integra 700) with a both inter-assay and intra-assay
coeﬃcient of variation of 2% and 1.5% for Apo AI, and
2.1% and 0.66% for Apo B, respectively. The sensitivity
is 0.19mg/dL for Apo AI and 0.052mg/dL for Apo B.
The HbA1c was measured using a commercial kit (Gly-
cotest 2; Pierce, Rockford, IL). Serum CRP concentration
was measured by immunoturbidimetry with latex particles
sensitized with speciﬁc antibodies [34–36]( C o b a sI n t e g r a
700, Roche) with a both inter-assay and intra-assay coef-
ﬁcient of variation of 2.9% and 1.8%, and sensitivity of
0.085mg/dL. The creatinine was measured by Jaﬀe kinetic
reaction buﬀerwithoutdeproteinization[37–39]withaboth
inter-assay and intra-assay coeﬃcient of variation of 3.8%
and 0.8%, and sensitivity of 0.017mg/dL. From the plasma,
LDL fraction from each sample was isolated by sequential
preparative ultracentrifugation using a Beckman ultracen-
trifuge as described by Sattler et al. [40]. After centrifugation
at 100000rpm during 2h at 15◦C in a Beckman TLA 100.4
rotor, the LDL fractions were collected with a syringe, and
protein composition was measured by commercial assay
(Pierce method, Rockford, IL, USA) using bovine serum
albumin as a standard. Conjugated diene formation was
determined spectrophotometrically by the measure of the
absorbance at 234nm (U-3000 spectrophotometer, Hitachi).
Plasma was diluted (1/100) with phosphate buﬀer before
each measure. LDL at concentration of 100mg/mL under-
went in vitro oxidation induced by incubation with 10Mm
CuSO4 at 37◦C. The kinetics of conjugated dienes formation
was continuously monitored by measuring the absorbance
at 234nm, every 10min for at least 8h. The lag phase
(LP) of conjugated dienes formation, maximal rate of dienes
production (MR), and maximum dienes production was
determined according to the method of Kleinveld [41].
2.7. Statistical Analysis. Statistical analysis was done using
SPSS 17.0 software and using the student test for compar-
ison of two means. The results are expressed as mean ±
standard deviation. Diﬀerence in LDL susceptibility to lipid
peroxidation was analyzed by the Wilcoxon signed rank test.
Diﬀerences are considered signiﬁcant when the P value is
<0.05.
3. Results
The baseline characteristics of the patients, including sex and
age as well as the risk factors associated with atherosclerosis
diseases, are detailed in Table 2. Average glycemic control
was poor (>7%). Indeed, the mean of HbA1c in both
argan oil and control group was 8.8% and 9%, respectively.4 International Journal of Endocrinology
Table 2:Baselineanthropometricalandbiologicalcharacteristicsof
both study groups.
Characteristics Argan oil group Control group
M/W 23/20 22/21
Age (years) 52.09 ± 10.75 52.29 ± 10.51
Diabetes (years) 7.63 ± 4.34 7.71 ± 4.8
Family history (%) 19.56 15.38
SBP (mmHg) 12.00 ± 2.42 12.77 ± 2.43
DBP (mmHg) 7.67 ± 1.28 7.74 ± 1.34
Hypertension (%) 26.08 23.03
Weight (kg) 75.61 ± 13.08 76.03 ± 13.25
BMI (kg/m2) 29.67 ± 5.00 29.71 ± 4.90
Overweight (%) 26.08 25.64
Obesity (%) 19.57 21.76
Waist circumference (cm) 100.79 ± 15.46 102 ± 14.92
Metabolic syndrome
according to IDF deﬁnition % 49.34 51.84
TC (mg/dL) 197 ± 35 191 ± 37
TG (mg/dL) 152 ± 55 150 ± 56
HDL-chol (mg/dL) 39 ± 73 4 ± 5
LDL-chol (mg/dL) 127 ± 39 127 ± 33
Apo B (mg/dL) 82.90 ± 20.13 86.83
Apo AI (mg/dL) 106.84 ± 17 106.24 ± 14
Apo B/Apo AI 0.65 0.66
HbA1C % 8.8 ± 19 ± 0.7
CRP (mg/dL) 5.22 ± 1.7 5.34 1.4
Creatinine (mg/dL) 6.1 ± 1.16 6.07 ± 1.2
Lag time (min) 52.70 53
MR (mol diene/mol
LDL/min) 3.83 3.86
MDP (mol diene/mol LDL) 520.17 521.80
Abbreviations: Apo AI: apolipoprotein AI; Apo B: apolipoprotein B; BMI:
body mass index; CRP: C-reactive protein; DBP: diastolic blood pres-
sure; HDL-chol: high density lipoprotein cholesterol; IDF: International
Diabetes Federation; LDL-chol: low density lipoprotein cholesterol; M:
men; MDP: maximum diene production; MR: maximal rate; TC: total
c h o l e s t e r o l ;T G :t r i g l y c e r i d e s ;W :w o m e n .
According to the International Diabetes Federation deﬁni-
tion (IDF) [42], the metabolic syndrome (MS) percentage
in both groups of argan oil and control was 49.34% and
51.15%, respectively. The most frequent components of the
metabolic syndrome in our diabetic patients in addition
to hyperglycemia were central obesity and high level of
plasma triglycerides. Total of the patients had at least two
MS components. In argan oil group, 40% of patients had
tree of the ﬁve IDF criteria, 50% had four, and 10% had
the ﬁve MS components. In control group, 30% of patients
had tree of the ﬁve IDF criteria, 66% had four, and 4%
had the ﬁve MS components. The Apo B/Apo AI ratio is
strongly associated with the presence of individual metabolic
syndrome components, with the metabolic syndrome itself,
and with insulin resistance. The Apo B/Apo AI ratio was
elevated in both argan oil and control group at baseline (0.65
and 0.66, resp.).
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Figure 2: Variations of diﬀerent parameters in argan oil groups
after three weeks of interventions. Abbreviations: Apo AI:
apolipoprotein AI; Apo B: apolipoprotein B; CRE: creatinine; CRP:
C-reactive protein; HDL-Chol: high density lipoprotein cholesterol;
LDL-chol: low density lipoprotein cholesterol; TC: total cholesterol;
TG: triglycerides; ∗ signiﬁcantly diﬀerent.
The analysis of diet questionnaire showed that 92% of
patients consume at least once a day fruits and vegetables,
55% consume at least once a day cereals and legumes.
However, only 50% consume meat, tea, and coﬀee at least
once a week, whereas no tendency to consume oils, fats, and
sugar was noted.
The results obtained after three weeks of intervention
with argan oil showed a signiﬁcant change in lipid parameter
and apolipoprotein AI (Table 3) .T h ec h a n g ei nC R Pa n d
Apolipoprotein B was not signiﬁcant but was a tendency of
reduction (a decrease of 5.85% and 3.65%, resp.) (Figure 2).
Serum triglycerides decreased by 11.84%, (P = 0.001), total
cholesterol by 9.13%, (P = 0.01), and LDL-chol by 11.81%
(P = 0.02). However, a signiﬁcant increase was observed in
HDL-chol and Apo AI plasma concentration (10.51%, P =
0.01 and 9.40% P = 0.045, resp.). Susceptibility of LDL to
lipid peroxidation was signiﬁcantly decreased by increasing
ofthelagphase(20.95%,P = 0.027)after3weeksofarganoil
intervention. The MR and MDP were signiﬁcantly decreased
(Table 4).
4. Discussion
The quality of fatty acids contained in argan oil and the
abundance of antioxidant compounds in the unsaponiable
fraction suggests a putative use for this oil in nutritional
prevention against some pathologies such as cardiovascular
diseases (CVD). However, only few studies have reported
beneﬁcial pharmacological eﬀects of argan oil and its com-
pounds in blood pressure, lipids and lipids peroxidation in
human and animal models [19–23]. This is probably related
to its fat composition, 45% monounsaturated fatty acids
(MUFA) and 35% polyunsaturated fatty acids (PUFA), and
to its minor compounds such as polyphenols, phytosterols,
andtocopherols[18].Thehypolipidemicandtheantioxidant
eﬀects of argan oil were demonstrated in healthy subjectInternational Journal of Endocrinology 5
Table 3: Variations of diﬀerent parameters in both groups after three weeks of intervention.
Groups Parameters
TC
(mg/dL)
TG
(mg/dL)
LDL-chol
(mg/dL)
HDL-chol
(mg/dL)
Apo AI
(mg/dL)
Apo B
(mg/dL)
ApoB/Apo
AI
CRP
(mg/dL)
CRE
(mg/dL)
C
o
n
t
r
o
l After stabilization
(2 weeks) 191 ±37 150 ±56 127 ±33 34 ±5 106.24±14 86.83 ±20.63 0.66 ±0.10 3.96 ±1.46 .07 ±1.2
After intervention
(3 weeks) 192 ±35 148±54 127 ±34 35 ±5 105.71±17 88.11 ±13.02 0.67 ± 0.17 4.0 ±1.56 .21 ±1.4
P 0.331 0.367 0.451 0.329 0.358 0.462 0.405 0.427 0.391
A
r
g
a
n
o
i
l After stabilization
(2 weeks) 197 ±35 152 ± 55 127 ±39 39 ±7 106.84±17 82.90 ±20.13 0.65 ±0.13 4.27 ±1.74 .65 ±1.16
After intervention
(3 weeks) 179 ±36 134±43 112 ±33 43 ±10 117.52±10 79.00 ±14.08 0.63 ±0.12 4.02 ±1.34 4.63 ±1.36
P 0.012 0.001 0.024 0.013 0.017 0.147 0.092 0.075 0.316
Abbreviations:ApoAI:apolipoproteinAI;ApoB:apolipoproteinB;CRE:creatinine;CRP:C-reactiveprotein;HDL-chol:highdensitylipoproteincholesterol;
LDL-chol: low density lipoprotein cholesterol; TC: total cholesterol; TG: triglycerides. Values are mean ± SD.
Table 4: Kinetic of conjugated dienes formation from oxidized LDL of both study groups after 3 weeks of argan oil intervention.
Groups Markers of susceptibility of LDL to lipid peroxidation
LP (min) MR (mol diene/mol LDL/min) MDP (mol diene/mol LDL)
Control
After stabilization (2 weeks) 53.45 3.83 520.17
After intervention (3 weeks) 52.70 3.86 521.80
P 0.189 0.207 0.180
Argan oil
After stabilization (2 weeks) 52.00 3.88 522.70
After intervention (3 weeks) 63.10 1.04 338.60
P 0.027 0.031 0.019
Abbreviations: LP: lag phase; MDP: maximum dienes production; MR: maximal rate of dienes production. Values are means ± SD.
[22, 23]. Another study showed that intake of argan oil,
improves insulin signaling in fat and liver beyond levels
found in a rat model of dietary-induced obesity [43].
The lipid lowering eﬀect of argan oil was investigated for
the ﬁrst time in diabetic patients, in this study and it could
be expected because of the interesting level of unsaturated
fats and the ratio of PUFA/SFA (3.34) and of MUFA/PUFA
(1.63) [20]. PUFA has protective eﬀects against oxidation, as
explained by the presence of the double bonds. Argan oil is
rich in oleic and linoleic acids that show less susceptibility
to peroxidation [20]. Moreover, linoleic acid derivatives,
particularly gamma-linolenic acid are shown potent in
reducing blood cholesterol in humans and rats [44–46].
Also, argan oil is rich in phytosterols known for their
beneﬁcial eﬀects on lipid markers [47–51]. The hypoc-
holesterolemic eﬀe c to fa r g a no i lm a yb ed u et oi t sh i g h
content in sterols in the minor compounds fraction. A
recent study shows that plant sterols in patients with
hypercholesterolemiareducetheconcentrationofcholesterol
in both LDL and small LDL which are considered the more
atherogenic particles [52, 53].
It is well documented that Apo AI is inversely correlated
to CVD risk as to HDL-chol level. Apo AI as HDL-chol
levels have signiﬁcantly increased after argan oil intervention
assuming that argan oil is antiatherogenic oil and could be
used as nutritional preventive oil.
The diabetic patients in this study present a tendency to
decrease the Apo B/Apo AI ratio after argan oil intervention,
while they have showed an elevated Apo B/Apo AI ratio at
baseline as in patients with metabolic syndrome, coronary
artery disease, and with ischemic stroke [54, 55].
The interesting ﬁnding of this study was the combination
of the decrease of triglycerides and Apo B/Apo AI ratio
and the increase of HDL-chol, obtained after argan oil con-
sumption which could reduce the percentage of metabolic
syndrome observed among the patients, thus giving a ben-
eﬁcial role in the management of metabolic complications
associated with metabolic syndrome in type 2 diabetics.
At the end of intervention period, we observed an
important and signiﬁcant increase of lag phase of conjugated
dienes formation in LDL oxidation. This may be explained
by the fact that isolated LDL particles from patients might
be enriched with diﬀerent antioxidants from argan oil diets,
reducing their susceptibility to lipid peroxidation [56, 57].
Drissi et al. [22] showed that sterol, tocopherol, and phenol
compounds from argan oil increase the resistance of LDL
to oxidation in healthy subjects. This study brings a new
demonstration of the antioxidant eﬀect of argan oil.
The trend of reduction of CRP is important considering
the improve of insulin sensitivity in target tissue and may
increase the ability of insulin to induce its beneﬁcial eﬀect
on lipid metabolism.6 International Journal of Endocrinology
5. Conclusion
Our ﬁndings show for the ﬁrst time that consumption of
argan oil may have an antiatherogenic eﬀect by improving
lipids and apolipoprotein AI and the susceptibility of LDL
to oxidation in type 2 diabetes patients with dyslipidemia
and can therefore be recommended in the nutritional
management of type 2 diabetes.
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